Prior studies have shown that pathways like PI3K/AKT [15], NF-κB [16], and Ras/MAPK [17] are frequently dysregulated in ESCC, driving tumor growth, metastasis, and resistance to therapy. This evidence concerns the gene PIK3CA and neoplasm.